Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer

被引：21

作者：

Thirion, P ^{[1
]}

Piedbois, P ^{[1
]}

Buyse, M ^{[1
]}

O'Dwyer, PJ ^{[1
]}

Cunningham, D ^{[1
]}

Man, A ^{[1
]}

Greco, FA ^{[1
]}

Colucci, G ^{[1
]}

Köhne, CH ^{[1
]}

Di Costanzo, F ^{[1
]}

Piga, A ^{[1
]}

Palmeri, S ^{[1
]}

Dufour, P ^{[1
]}

Cassano, A ^{[1
]}

Pajkos, G ^{[1
]}

Pensel, R ^{[1
]}

Aykan, NF ^{[1
]}

Marsh, J ^{[1
]}

Seymour, T ^{[1
]}

机构：

[1] Hop Henri Mondor, Dept Med Oncol, Assistance Publ Hop Paris, F-94000 Creteil, France

来源：

BRITISH JOURNAL OF CANCER | 2001年 / 84卷 / 05期

关键词：

5-fluorouracil; interferon; colorectal cancer; meta-analysis;

D O I：

10.1054/bjoc.2000.1669

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Two meta-analyses were conducted to quantify the benefit of combining alpha -IFN to 5FU in advanced colorectal cancer in terms of tumour response and survival. Analyses were based on a total of 3254 individual patient data provided by principal investigators of each trial. The meta-analysis of 5FU +/- LV vs. 5FU +/- LV + alpha -IFN combined 12 trials and 1766 patients. The meta-analysis failed to show any statistically significant difference between the two treatment groups in terms of tumour response or survival. Overall tumour response rates were 25% for patients receiving no alpha -IFN vs. 24% for patients receiving alpha -IFN (relative risk, RR = 1.02), and median survivals were 11.4 months for patients receiving no alpha -IFN vs. 11.5 months for patients receiving alpha -IFN (hazard ratio, HR = 0.95). The meta-analysis of 5FU + LV vs. 5FU + alpha -IFN combined 7 trials, and 1488 patients. This meta-analysis showed an advantage for 5FU + LV over 5FU + alpha -IFN which was statistically significant in terms of tumour response (23% vs. 18%; RR = 1.26; P = 0.042), and of a borderline significance for overall survival (HR = 1.11; P = 0.066). Metastases confined to the liver and primary rectal tumours were independent favourable prognostic factors for tumour response, whereas good performance status. metastases confined to the liver or confined to the lung, and primary tumour in the rectum were independent favourable prognostic factors for survival. We conclude that alpha -IFN does not increase the efficacy of 5FU or of 5FU + LV, and that 5FU + alpha -IFN is significantly inferior to 5FU + LV, for patients with advanced colorectal cancer. (C) 2001 Cancer Research Campaign.

引用

页码：611 / 618

页数：8

共 46 条

[1]

[Anonymous], 1989, Analysis of binary data

[2]

AYKAN NF, 1996, ANN ONCOL, V7, P42

[3]

Buyse M, 1996, J NATL CANCER I, V88, P252

[4]

CASSANO A, 1996, ANN ONCOL S1, V7, P69

[5]

Colucci G, 1999, CANCER, V85, P535, DOI 10.1002/(SICI)1097-0142(19990201)85:3<535::AID-CNCR4>3.0.CO

[6]

2-7

[7]

COX DR, 1972, J R STAT SOC B, V34, P187

[8]

DALLEY D, 1995, J CLIN ONCOL, V13, P921

[9]

DANHAUSER L, 1991, P AM ASSOC CANC RES, V32, P1052

[10] Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer [J].

de Gramont, A ;

Figer, A ;

Seymour, M ;

Homerin, M ;

Hmissi, A ;

Cassidy, J ;

Boni, C ;

Cortes-Funes, H ;

Cervantes, A ;

Freyer, G ;

Papamichael, D ;

Le Bail, N ;

Louvet, C ;

Hendler, D ;

de Braud, F ;

Wilson, C ;

Morvan, F ;

Bonetti, A .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) :2938-2947

← 1 2 3 4 5 →